Reata Pharmaceuticals, Inc. - Class A Analysis
| Analyst Ratings |
|
Average Target Price
|
62.40
|
|
Average Rating
|
4.33
|
|
# Strong Buys
|
5
|
|
# Buys
|
2
|
|
# Holds
|
2
|
|
# Sells
|
0
|
|
# Strong Sells
|
0
|
| Quarterly Earnings History |
| Quarter |
EPS Estimate |
EPS Actual |
EPS Difference |
Surprise Percent |
|
2022-09-30
|
-2.18
|
-2.16
|
0.02
|
0.92%
|
|
2022-06-30
|
-2.02
|
-2.02
|
0.00
|
0.00%
|
|
2022-03-31
|
-2.17
|
-2.03
|
0.14
|
6.45%
|
|
2021-12-31
|
-2.31
|
-2.35
|
-0.04
|
-1.73%
|
|
2021-09-30
|
-2.16
|
-1.97
|
0.19
|
8.80%
|
|
2021-06-30
|
-2.06
|
-2.00
|
0.06
|
2.91%
|
|
2021-03-31
|
-2.10
|
-1.86
|
0.24
|
11.43%
|
|
2020-12-31
|
-2.16
|
-1.90
|
0.26
|
12.04%
|
| Annual Earnings History |
| Fiscal Year End |
EPS |
|
2022-12-31
|
-6.21
|
|
2021-12-31
|
-8.18
|
|
2020-12-31
|
-7.34
|
|
2019-12-31
|
-9.35
|
|
2018-12-31
|
-2.86
|
|
2017-12-31
|
-1.98
|
|
2016-12-31
|
-0.29
|